Core Viewpoint - Zepp Health's stock price has more than doubled in the past two weeks, with a forecast of 30% revenue growth in Q2, marking the first year-on-year increase in three years [1][6] Group 1: Company Transformation - Zepp Health is transitioning from being a contract manufacturer for Xiaomi to developing its own brand, Amazfit, which is expected to drive growth [3][5] - The company has seen a significant decline in revenue due to its previous reliance on Xiaomi, but is now experiencing a recovery as it focuses on its own brand [5][6] Group 2: Market Dynamics - The cases of Zepp and New Oxygen reflect a shift in investor perception, recognizing that not all Chinese companies should be viewed with the same skepticism [4] - Despite recent stock price increases, Zepp's price-to-sales ratio remains low at 0.46, indicating potential for further upside compared to global competitors [4][5] Group 3: Financial Performance - In Q1, Zepp reported a slight revenue decline of 3.6% to $38.5 million, but anticipates a 30% revenue growth in Q2 [6] - The company is still operating at a loss, with a net loss of $19.7 million in Q1, although it is optimistic about future growth and margin improvements [6][7] Group 4: Product Development - The anticipated revenue growth is attributed to the successful launch of two new products, Amazfit Active 2 and Bip 6, which have received positive market feedback [6] - The company is addressing supply chain bottlenecks and aims to resolve these issues by the end of June [6]

Core Insights - Zepp Health Corporation reported a 10% year-over-year growth in Amazfit revenue for Q1 2025, despite a challenging macroeconomic environment [1][3][6] - The company successfully launched new smartwatch models, Amazfit Active 2 and Bip 6, which have received positive market reception and are expected to drive further sales growth [1][2][6] - The management anticipates a year-over-year revenue increase for Q2 2025, projecting net revenues between US$50 million and US$55 million, representing a growth of approximately 23% to 35% compared to Q2 2024 [3][21] Financial Performance - Total revenue for Q1 2025 was US$39 million, with Amazfit-branded products growing by 10.2% year-over-year [3][6] - Gross margin improved to 37.3%, up from 36.8% in the same period last year, despite facing additional tariffs [3][7] - The net loss for Q1 2025 was US$19.7 million, compared to a net loss of US$14.8 million in Q1 2024 [15][33] Operating Expenses - Total operating expenses for Q1 2025 were US$32.7 million, a 6.9% increase year-over-year, driven by higher selling and marketing expenses [12][9] - Research and development expenses decreased by 7.8% year-over-year to US$12.4 million, reflecting a focus on resource efficiency [8] - Selling and marketing expenses rose by 28.5% year-over-year to US$13.8 million, primarily due to investments in digital campaigns and product launches [9][12] Cash and Debt Management - The company had a cash balance of US$104 million as of March 31, 2025, after repaying US$11.5 million in short-term debt [3][4] - Long-term borrowings now represent about 70% of total debt, with US$67.8 million of debt retired since early 2023 [4][18] - Improved working capital management contributed to a tighter cash conversion cycle, allowing for continued investment in growth opportunities [16][18] Market Strategy and Outlook - Zepp Health is committed to leveraging open-source technologies and enhancing AI capabilities to improve product offerings and user experience [2] - The company is expanding its brand presence through partnerships with athletes and community events, aiming to strengthen user connections and broaden its market reach [2][21] - Management remains focused on optimizing the supply chain and investing in AI-driven experiences to maintain leadership in the wearable market [2][21]